StockData

KALA BIO, Inc. (KALA) stock

KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 5/30
$3.26−0.17 (-4.96%)

Close on Nov 18, 2026Market cap $63.05MP/E –Yield –

Kala Bio operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Kala Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$19.86M. For fiscal 2025 it was -$31.99M. The highest annual figure on record is -$15.09M in fiscal 2015.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$31.99M–
FY2024Dec 31, 2024-$29.38M–
FY2023Dec 31, 2023-$27.93M–
FY2022Dec 31, 2022-$78.91M–
FY2021Dec 31, 2021-$108.24M–
FY2020Dec 31, 2020-$90.69M–
FY2019Dec 31, 2019-$92.72M–
FY2018Dec 31, 2018-$54.12M–
FY2017Dec 31, 2017-$34.10M–
FY2016Dec 31, 2016-$27.35M–
FY2015Dec 31, 2015-$15.09M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.54M–
Q1 FY2026Mar 31, 2026-$2.90M–
Q4 FY2025Dec 31, 2025-$4.56M–
Q3 FY2025Sep 30, 2025-$10.88M–
Q2 FY2025Jun 30, 2025-$16.56M–
Q1 FY2025Mar 31, 2025-$8.82M–
Q4 FY2024Dec 31, 2024-$4.60M–
Q3 FY2024Sep 30, 2024-$4.73M–
Q2 FY2024Jun 30, 2024-$9.22M–
Q1 FY2024Mar 31, 2024-$10.84M–
Q4 FY2023Dec 31, 2023-$7.70M–
Q3 FY2023Sep 30, 2023-$2.95M–
Q2 FY2023Jun 30, 2023-$7.60M–
Q1 FY2023Mar 31, 2023-$9.68M–
Q4 FY2022Dec 31, 2022-$13.74M–
Q3 FY2022Sep 30, 2022-$15.67M–
Q2 FY2022Jun 30, 2022-$25.42M–
Q1 FY2022Mar 31, 2022-$24.09M–
Q4 FY2021Dec 31, 2021-$27.90M–
Q3 FY2021Sep 30, 2021-$26.08M–
Q2 FY2021Jun 30, 2021-$21.61M–
Q1 FY2021Mar 31, 2021-$32.64M–
Q4 FY2020Dec 31, 2020-$25.92M–
Q3 FY2020Sep 30, 2020-$25.64M–
Q2 FY2020Jun 30, 2020-$19.25M–
Q1 FY2020Mar 31, 2020-$19.88M–
Q4 FY2019Dec 31, 2019-$18.21M–
Q3 FY2019Sep 30, 2019-$22.91M–
Q2 FY2019Jun 30, 2019-$20.43M–
Q1 FY2019Mar 31, 2019-$31.17M–
Q4 FY2018Dec 31, 2018-$15.99M–
Q3 FY2018Sep 30, 2018-$16.21M–
Q2 FY2018Jun 30, 2018-$9.21M–
Q1 FY2018Mar 31, 2018-$12.71M–
Q4 FY2017Dec 31, 2017-$6.56M–
Q3 FY2017Sep 30, 2017-$9.33M–
Q2 FY2017Jun 30, 2017-$8.85M–
Q1 FY2017Mar 31, 2017-$9.36M–
Q4 FY2016Dec 31, 2016-$7.33M–
Q3 FY2016Sep 30, 2016-$8.15M–

More Kala Bio figures

See a number that looks wrong?